ExploreWatchlistsPricing
  1. JP-listed companies
  2. D.Western Therapeutics Institute, Inc.
  3. Financials
  4. Effective tax rate (%)

D.Western Therapeutics Institute, Inc. (4576)

Market cap
¥5.2B
P/E ratio
-6.4x
De Western Therapeutics Institute develops protein kinase inhibitor drugs for eye diseases and licenses them to pharmaceutical companies for commercialization.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndEffective tax rate (%) (Million JPY)YoY (%)
Dec 31, 2025-0.3+94.78%
Dec 31, 2024-0.1-35.15%
Dec 31, 2023-0.2-62.86%
Dec 31, 2022-0.5-46.01%
Dec 31, 2021-1+81.28%
Dec 31, 2020-0.6-137.85%
Dec 31, 20191.5-840.24%
Dec 31, 2018-0.2-28.52%
Dec 31, 2017-0.3-52.39%
Dec 31, 2016-0.6+55.42%
Dec 31, 2015-0.4-25.46%
Dec 31, 2014-0.5

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat